Scenarios | 2020 | 2022 | 2023 | 2024 | 2025 | 2030 |
---|---|---|---|---|---|---|
Treated | ||||||
Standard of Care prior to 2022 | 930 | 960 | 960 | 960 | 960 | 960 |
Screening Program | 930 | 1570 | 3700 | 960 | 960 | 960 |
WHO Elimination | 930 | 1570 | 3700 | 2180 | 2180 | 2180 |
Viraemic newly diagnosed | ||||||
Standard of Care prior to 2022 | 1520 | 1920 | 1920 | 1920 | 1920 | 1920 |
Screening Program | 930 | 4360 | 7410 | 960 | 960 | 960 |
WHO Elimination | 930 | 4360 | 7410 | 500 | 500 | 500 |
Liver fibrosis stage for treatment eligibility, | ||||||
Standard of Care prior to 2022 | ≥F2 | ≥F2 | ≥F2 | ≥F2 | ≥F2 | ≥F2 |
Screening Program | ≥F2 | ≥F2 | ≥F2 | ≥F2 | ≥F2 | ≥F2 |
WHO Elimination | ≥F2 | ≥F2 | ≥F2 | ≥F0 | ≥F0 | ≥F0 |
Anti-HCV tests | ||||||
Screening Program | 460,250 | 851,380 | ||||
WHO Elimination | 460,250 | 851,380 | 488,370 | 740 | 270 | |
Incident cases of chronic HCV* | ||||||
Screening Program | 610 | 580 | 570 | 560 | 550 | 500 |
WHO Elimination | 610 | 580 | 570 | 520 | 450 | 160 |
Age limits for treatment eligibility* | ||||||
Screening Program | 15–74 | 15–74 | 15–74 | 15–74 | 15–74 | 15–74 |
WHO Elimination | 15–74 | 15–74 | 15–74 | 15–84 | 15–84 | 15–84 |
Sustained virological response | 99% | 99% | 99% | 99% | 99% | 99% |